Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions.

Next Previous
X
Search
Trial Profile

SPIRIT V: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-V-Diabetic Study
  • Sponsors Abbott Laboratories

    • Most Recent Events

    • 01 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jul 2010 There will be no further follow-up in this trial, as reported by ClinicalTrials.gov.
    • 25 May 2010 Nine-month angiographic and one-year clinical results for the SPIRIT V Diabetic study were presented at EuroPCR 2010 according to an Abbott media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top